Medicines Co. buy tamam
Start price
31.08.17
/
50%
€32.98
Target price
13.06.19
€45.10
Performance (%)
-0.55%
End price
13.06.19
€32.80
Summary
This prediction ended on 13.06.19 with a price of €32.80. The BUY prediction by tamam for Medicines Co. closed nearly unchanged. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Medicines Co. | - | - | - | - |
| iShares Core DAX® | 0.597% | 3.083% | 16.090% | 16.439% |
| iShares Nasdaq 100 | 0.899% | 5.338% | 29.239% | 56.431% |
| iShares Nikkei 225® | 1.775% | -1.206% | 6.823% | 4.774% |
| iShares S&P 500 | 0.990% | 3.500% | 24.956% | 47.182% |
Comments by tamam for this prediction
In the thread Medicines Co. diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
The Medicines Company (NASDAQ:MDCO) announced that it had received FDA approval for its drug VABOMERE. This drug is used to treat adult patients with complicated urinary tract infections
(cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae.
(cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae.
(Laufzeit überschritten)